CClinicalTrials.gg
CompletedNCT03700710Updated Jul 28, 2021

Remote Dietary Counseling to Promote Healthy Diet and Blood Pressure

An interventional study of Self-Guided Approach and Dietitian-led Approach in Blood Pressure, High Blood Pressure and Dietary Modification, sponsored by Geisinger Clinic. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-28.

Sponsored by Geisinger Clinic · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines recommend lifestyle modification for patients with elevated blood pressure. While eating a Dietary Approaches to Stop Hypertension (DASH)-type diet, increasing physical activity, and weight loss have been shown to reduce blood pressure, limited resources are available in the primary care setting to help patients make these changes.

In this study, the investigators will compare the efficacy of a self-guided vs. dietitian-led approach using web-based lifestyle modification tools to reduce weight, improve dietary quality, and lower blood pressure in overweight/obese adults with elevated blood pressure.

Read the detailed description

Goals that all participants will be instructed to target include: 1) weight loss >=3% at 3 months; 2) consume a healthier dietary pattern (high in fruits, vegetables, whole grains, low-fat dairy, vegetable/fish/poultry sources of protein, healthier sources of fat, and avoid sugar and salt); 3) reduce sodium intake to \<2300 mg/d; 4) at least 180 min/wk of moderate-intensity physical activity.

02

Conditions studied

  • Blood Pressure
  • High Blood Pressure
  • Dietary Modification
  • Overweight and Obesity

Keywords

  • lifestyle modification
  • DASH diet
  • weight loss
  • exercise
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 187 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Geisinger Clinic is the lead sponsor of 125 studies on the registry; 21 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 24-hour ambulatory SBP 120-160 mmHg
  • BMI ≥ 25 kg/m2
  • Access to a telephone
  • Access to a computer or smartphone with internet access
  • Complete dietary data entry for at least 5 out of 7 days during run-in period
  • Enter weight into the platform during run-in period

Exclusion criteria

Exclusion Criteria:

  • Inability to understand English
  • Myocardial infarction, stroke, or atherosclerotic cardiovascular disease procedure within last 6 months.
  • Current treatment for malignancy
  • Planned or previous bariatric surgery
  • Pregnant, breast-feeding, or planned pregnancy prior to the end of participation
  • Self-reported average consumption of > 21 alcoholic beverages per week or binge drinking.
  • Psychiatric hospitalization in past year
  • Current symptoms of angina
  • Planning to leave the area prior to end of the study
  • Current participation in another clinical trial
  • Principal investigator discretion (i.e. concerns about safety, compliance)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
187 participants (actual)

Study arms

  • Active comparator
    Self-Guided Approach

    In the self-guided arm, participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure. The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry.

    Behavioral: Self-Guided Approach

  • Experimental
    Dietitian-led Approach

    In the dietitian-led arm, dietitian will use motivational interviewing in 15-30 minute telephone calls with participants. The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry. The web platform will be used to share participant dietary and weight data with dietitians.

    Behavioral: Dietitian-led Approach

Interventions

  • BehavioralSelf-Guided Approach

    For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information. From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform. In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.

  • BehavioralDietitian-led Approach

    For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information. From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform. In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform. Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis.

06

What researchers measure

Primary outcomes

  1. Change in 24-hour Systolic Blood Pressure

    Measured by 24-hour ambulatory blood pressure monitoring (SpaceLabs Ontrak)

    Time frame: Baseline to 12-week follow-up

Secondary outcomes

  1. Change in 24-hour diastolic blood pressure

    Measured by 24-hour ambulatory blood pressure monitoring (SpaceLabs Ontrak)

    Time frame: Baseline to 12-week follow-up

  2. Change in Daytime Systolic Blood Pressure

    Measured by 24-hour ambulatory blood pressure monitoring (SpaceLabs Ontrak)

    Time frame: Baseline to 12-week follow-up

  3. Change in Nighttime Systolic Blood Pressure

    Measured by 24-hour ambulatory blood pressure monitoring (SpaceLabs Ontrak)

    Time frame: Baseline to 12-week follow-up

  4. Change in Daytime Diastolic Blood Pressure

    Measured by 24-hour ambulatory blood pressure monitoring (SpaceLabs Ontrak)

    Time frame: Baseline to 12-week follow-up

  5. Change in Nighttime Diastolic Blood Pressure

    Measured by 24-hour ambulatory blood pressure monitoring (SpaceLabs Ontrak)

    Time frame: Baseline to 12-week follow-up

  6. Change in Total Healthy Eating Index - 2015 score

    Assessed by Viocare Food Frequency Questionnaire (score 0-100, 100=best possible score)

    Time frame: Baseline to 12-week follow-up

  7. Change in Weight

    Weight measured at baseline and 12-week visits without shoes

    Time frame: Baseline to 12-week follow-up

  8. Change in Waist Circumference

    Measured using a tape measure

    Time frame: Baseline to 12-week follow-up

  9. Change in Physical Activity (metabolic equivalent of task [MET]-minute per week

    Measured by International Physical Activity Questionnaire (IPAQ) Short Form

    Time frame: Baseline to 12-week follow-up

Other outcomes

  1. Change in individual components of Healthy Eating Index score

    Each individual component of the Healthy Eating Index score will be examined

    Time frame: Baseline to 12-week follow-up

  2. Satisfaction with the Healthy BP Research Study

    5-point Likert score

    Time frame: 12-week follow-up

07

Study locations

2 sites
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Geisinger Wyoming Valley
    Wilkes-Barre, Pennsylvania 18711, United States
08

References and documents

Publications

  • Chang AR, Gummo L, Yule C, Bonaparte H, Collins C, Naylor A, Appel LJ, Juraschek SP, Bailey-Davis L. Effects of a Dietitian-Led, Telehealth Lifestyle Intervention on Blood Pressure: Results of a Randomized, Controlled Trial. J Am Heart Assoc. 2022 Oct 4;11(19):e027213. doi: 10.1161/JAHA.122.027213. Epub 2022 Sep 29. PubMed 36172955 ↗
  • Taher M, Yule C, Bonaparte H, Kwiecien S, Collins C, Naylor A, Juraschek SP, Bailey-Davis L, Chang AR. Telehealth versus self-directed lifestyle intervention to promote healthy blood pressure: a protocol for a randomised controlled trial. BMJ Open. 2021 Mar 3;11(3):e044292. doi: 10.1136/bmjopen-2020-044292. PubMed 33658261 ↗

Individual participant data

Plan to share: Yes — The study protocol, statistical analysis plan, informed consent form, analytic code, and clinical study report will be shared at the time of publication of the main trial results; these data will be deidentified. These data will be publicly available indefinitely.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03700710
Lead sponsor
Geisinger Clinic
Responsible party
Sponsor
First posted
Oct 9, 2018
Start date
Jan 16, 2019
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Jul 28, 2021

Study contacts

Alexander Chang, MD
principal investigator · Geisinger Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion